Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study)
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Endocrine Society
This publication has 28 references indexed in Scilit:
- Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of DiabetesJournal of Diabetes Science and Technology, 2015
- Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS CohortPLOS ONE, 2014
- Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) studyThe Lancet Diabetes & Endocrinology, 2014
- Variables Involved in the Discordance between HbA1c and Fructosamine: The Glycation Gap RevisitedPLOS ONE, 2013
- Cancer with Diabetes: Prevalence, Metabolic Control, and Survival in an Academic Oncology PracticeEndocrine Practice, 2012
- Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrumNature Reviews Endocrinology, 2010
- Diabetes and CancerDiabetes Care, 2010
- Part I: Liver function in oncology: biochemistry and beyondThe Lancet Oncology, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesAnnals of Internal Medicine, 2007
- Inhibition of Albumin Synthesis in Chronic DiseasesJournal of Clinical Gastroenterology, 2005